美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

减肥药

1,257.83

+13.801.11%

涨家数：6

跌家数：1

平家数：- -

市盈率：- -

高：1,263.83

开：1,245.45

低：1,245.45

收：1,244.03

数据加载中...

诺和诺德(NVO.N)跌幅收窄至1.4%。

辉瑞6月2日成交额为7.13亿美元

诺和诺德6月2日成交额为12.15亿美元

港股异动 | 三生制药(01530)早盘涨超6% 公司与辉瑞达成重磅授权有望大幅增厚今年利润

安进6月2日成交额为6.89亿美元

围绕ActRII通路礼来与来凯医药(02105)将在2025ADA上“双龙戏珠”

分子胶赛道狂飙！罗氏、礼来、艾伯维众MNC齐押注

明晟公司MSCI北欧国家指数涨0.6%，报358.57点，北欧医疗保健板块领跑。诺和诺德涨4.7%，领跑一众成分股。

Altimmune, Inc.盘中异动早盘急速下跌5.16%报5.15美元

安进公司药物可将小细胞肺癌死亡风险降低 40

辉瑞占先发优势，Alnylam、BridgeBio紧跟，ATTR-CM三强鏖战

医药经济报

辉瑞：2 款创新 ADC 联合 K 药数据首次公布！恩扎卢胺 5 年 OS 率超 65 %...

Insight数据库

诺和诺德盘中异动急速上涨3.02%报71.56美元

美国疾病预防控制中心继续推荐健康儿童接种 COVID 疫苗

辉瑞5月29日成交额为6.12亿美元

安进5月29日成交额为7.91亿美元

财说｜一桩交易重构双抗药物市场，康方生物为何“受伤”？

健康查房：安进公司的血小板促进剂帮助需要化疗的患者

礼来反超：减肥药市场"老二"如何击败"老大"诺和诺德

华尔街见闻

平安健康携手诺和诺德，开创肥胖症管理服务新模式

企业观察网

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK4599/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"减肥药","latestPrice":1257.8302,"timestamp":1749239999999,"preClose":1244.0306,"halted":0,"volume":51513461,"delay":0,"changeRate":0.011093,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":13.799561,"latestTime":"06-06 16:00:00 EDT","open":1245.4493,"high":1263.8325,"low":1245.4493,"amount":3711906755.507839,"amplitude":0.014777,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.690713,"peRate":32.301623,"turnoverRate":0.004869,"increases":6,"decrements":1,"flats":0,"marketCap":1354591922304,"floatMarketCap":1258679594368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1263.8325,"amplitude":0.014777,"preClose":1244.0306,"low":1245.4493,"pbRate":"9.690713","latestPrice":1257.8302,"volume":51513461,"delay":0,"open":1245.4493,"prevYearClose":1305.0607,"prevWeekClose":1216.6,"prevMonthClose":1216.6,"prevQuarterClose":1314.3724,"fiveDayClose":1216.6,"twentyDayClose":1196.4727,"sixtyDayClose":1333.0085,"secType":"PLATE","market":"US","turnoverRate":0.004869,"peRate":32.301623,"marketCap":1354591922304,"floatMarketCap":1258679594368,"timestamp":1749239999999,"nameCN":"减肥药"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":6,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540277245","title":"诺和诺德(NVO.N)跌幅收窄至1.4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2540277245","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540277245?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 21:45","pubTimestamp":1748958337,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1093756325.SGD","IE00BKVL7J92.USD","BK4588","BK4599","BK4007","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","NVO","BK4585","BK4532"],"gpt_icon":0},{"id":"2540466727","title":"辉瑞6月2日成交额为7.13亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540466727","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540466727?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 11:43","pubTimestamp":1748922197,"startTime":"0","endTime":"0","summary":"美东时间2025年6月2日，辉瑞成交额为7.13亿美元，成交额较昨日减少46.40%，当日成交量为3044.39万股。辉瑞于2025年6月2日跌0.13%，报23.46美元，该股过去5个交易日涨0.6%，年初至今跌8.39%，过去60日跌8.89%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-02|7.13亿|-46.40%|3044.39万|#|2025-05-30|13.30亿|117.19%|5661.85万|#|2025-05-29|6.12亿|-28.44%|2621.01万|#|2025-05-28|8.56亿|0.45%|3673.72万|#|2025-05-27|8.52亿|3.57%|3615.54万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603114325a4979708&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603114325a4979708&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0306807586.USD","BK4599","LU0225284248.USD","BK4592","LU1894683264.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU1023059063.AUD","PFE","SG9999001176.USD","LU1883839398.USD","LU0058720904.USD","LU0289739699.SGD","LU0321505868.SGD","SG9999011175.SGD","LU1066051498.USD","SG9999002224.SGD","BK4585","LU0122379950.USD","IE000M9KFDE8.USD","LU0306806265.USD","BK4581","LU0985481810.HKD","LU0456855351.SGD","SG9999002232.USD","SGXZ57979304.SGD","BK4534","IE00B19Z3581.USD","BK4588","SG9999001176.SGD","LU0225771236.USD","IE0002270589.USD","LU0321505439.SGD","LU0170899867.USD","IE00BLSP4239.USD","BK4568","BK4550","SG9999003800.SGD","IE00B19Z3B42.SGD","BK4007","IE00BBT3K403.USD","LU1066053197.SGD","LU1894683348.USD","SG9999013999.USD","BK4533","LU0868494617.USD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2540745932","title":"诺和诺德6月2日成交额为12.15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540745932","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540745932?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 11:28","pubTimestamp":1748921304,"startTime":"0","endTime":"0","summary":"美东时间2025年6月2日，诺和诺德成交额为12.15亿美元，成交额较昨日增加53.35%，当日成交量为1680.79万股。诺和诺德于2025年6月2日涨1.86%，报72.83美元，该股过去5个交易日涨8.14%，年初至今跌14.19%，过去60日跌16.19%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603112834a6f7f24f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603112834a6f7f24f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4585","LU1093756168.USD","NVO","BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4588","LU0154236417.USD","IE00BKVL7J92.USD","BK4599"],"gpt_icon":1},{"id":"2540745566","title":"港股异动 | 三生制药(01530)早盘涨超6% 公司与辉瑞达成重磅授权 有望大幅增厚今年利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2540745566","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540745566?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 11:19","pubTimestamp":1748920766,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药早盘涨超6%，截至发稿，涨4.75%，报19.86港元，成交额7.69亿港元。消息面上，三生制药此前宣布，将其自主研发的PD-1/VEGF双特异性抗体SSGJ-707在全球的独家开发、生产、商业化权利授予全球药企巨头辉瑞。根据许可协议，辉瑞将支付12.5亿美元不可退还的首付款，以及最高可达48亿美元的里程碑付款和两位数百分比的销售分成。该行预计，辉瑞将在年内支付首付款，增厚三生制药的税前利润约11.75亿美元；同时未来会获得潜在里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1300543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 三生制药(01530)早盘涨超6% 公司与辉瑞达成重磅授权 有望大幅增厚今年利润","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0225284248.USD","LU0234572021.USD","LU0289739699.SGD","SG9999002232.USD","LU1066053197.SGD","BK4007","LU0122379950.USD","SG9999013999.USD","BK1593","BK4568","LU0456855351.SGD","BK4588","BK4534","IE000M9KFDE8.USD","LU1023059063.AUD","SG9999001176.USD","SG9999003800.SGD","LU1057294990.SGD","LU0985481810.HKD","LU1894683348.USD","IE00BLSP4452.SGD","BK4581","SG9999001176.SGD","BK4592","LU0868494617.USD","LU0306807586.USD","LU1894683264.USD","LU0058720904.USD","LU0306806265.USD","01530","LU0321505439.SGD","BK4533","BK1583","IE00B19Z3581.USD","IE00BBT3K403.USD","SG9999002224.SGD","SGXZ57979304.SGD","BK4585","LU1066051498.USD","IE0002270589.USD","SG9999011175.SGD","BK4599","IE00B19Z3B42.SGD","LU1883839398.USD","IE00BLSP4239.USD","BK1161","LU0321505868.SGD","BK4550","LU0225771236.USD"],"gpt_icon":0},{"id":"2540717258","title":"安进6月2日成交额为6.89亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540717258","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540717258?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 09:16","pubTimestamp":1748913373,"startTime":"0","endTime":"0","summary":"美东时间2025年6月2日，安进成交额为6.89亿美元，成交额较昨日减少55.89%，当日成交量为239.44万股。安进于2025年6月2日涨0.1%，报288.47美元，该股过去5个交易日涨6.19%，年初至今涨12.56%，过去60日跌8.43%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603091626a6f7c79b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603091626a6f7c79b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0289739699.SGD","LU0889565916.HKD","LU1571399168.USD","LU2089984988.USD","IE00BJT1NW94.SGD","LU1983299246.USD","BK4533","IE00B2B36J28.USD","LU2242652126.USD","BK4599","LU0058720904.USD","LU2112291526.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2242646821.SGD","BK4566","IE0002141913.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU0320765992.SGD","LU0122379950.USD","AMGN","BK4585","BK4534","BK4581","LU1057294990.SGD","SG9999001440.SGD","IE0009355771.USD","LU1061106388.HKD","BK4588","LU0868494617.USD"],"gpt_icon":0},{"id":"2540375712","title":"围绕ActRII通路 礼来与来凯医药(02105)将在2025ADA上“双龙戏珠”","url":"https://stock-news.laohu8.com/highlight/detail?id=2540375712","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540375712?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 09:08","pubTimestamp":1748912938,"startTime":"0","endTime":"0","summary":"令人注意的是，围绕ActRII通路，礼来的ActRIIA/B抗体Bimagurmab与司美格鲁肽联用的二期研究结果将在6月23日ADA大会上有一个半小时的专题报道，可见该数据的整体重要性。早一天，潜在国产同类最佳来凯医药的ActRIIA抗体LAE102将公布首次人体研究数据，上演一出“双龙戏珠”。好戏开演，ActRII通路正在成为巨额deal诞生的温床。ActRII通路的配体抑制开发路线创新分子，率先为赛道发声。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1300476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0889565916.HKD","LU1868836591.USD","LU2237443465.HKD","LU2750360997.AUD","IE00BK4W5M84.HKD","BK4599","SG9999014906.USD","LU1064131342.USD","LU1868836914.USD","SG9999014898.SGD","LU2265009873.SGD","LU2491049909.HKD","LU2324357040.USD","LU0471298777.SGD","LU2211815571.USD","LU2360106947.USD","LU0203201768.USD","LU0203202063.USD","LU0689472784.USD","LU1804176565.USD","LU0823416689.USD","LU2357305700.SGD","IE0009355771.USD","LU1280957306.USD","BK4533","02105","LU1989771016.USD","SG9999013999.USD","LU2471134952.CNY","LU1988902786.USD","LU2750360641.GBP","SG9999018857.SGD","BK4585","LU1093756325.SGD","SG9999015978.USD","SGXZ99366536.SGD","LU0079474960.USD","LU0256863811.USD","SGXZ31699556.SGD","IE0004445239.USD","LU0058720904.USD","LU0882574139.USD","LU1232071149.USD","LU2106854487.HKD","GB00BDT5M118.USD","SGXZ51526630.SGD","LLY","LU0109391861.USD","LU2552382132.HKD","LU2552382215.SGD"],"gpt_icon":1},{"id":"2540711585","title":"分子胶赛道狂飙！罗氏、礼来、艾伯维众MNC齐押注","url":"https://stock-news.laohu8.com/highlight/detail?id=2540711585","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540711585?lang=zh_cn&edition=fundamental","pubTime":"2025-06-03 07:31","pubTimestamp":1748907101,"startTime":"0","endTime":"0","summary":"分子胶是近年来备受关注的革命性药物开发策略。近年来，罗氏、诺和诺德、艾伯维、礼来等制药巨头纷纷进军癌症、免疫学等其他应用的分子胶领域。值得注意的是，与Neomorph的合作并不是艾伯维首次布局分子胶蛋白降解剂赛道。2024年10月29日，Biogen和Neomorph宣布达成合作，开发用于治疗阿尔茨海默病、罕见神经疾病和免疫疾病的分子胶降解剂。Neomorph将获得预付款，并有资格获得里程碑付款，总金额高达14.5亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603073433a4974997&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603073433a4974997&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2357305700.SGD","BK4581","LU0471298777.SGD","LU0456855351.SGD","SG9999015945.SGD","LU1720051108.HKD","LU0417517546.SGD","SG9999018857.SGD","LU2237443978.SGD","LU0320765992.SGD","LU1989771016.USD","LU1804176565.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU0672654240.SGD","LU2552382215.SGD","LU0820561909.HKD","LU1814569148.SGD","SG9999017495.SGD","LU0109394709.USD","LU1551013342.USD","LU0943347566.SGD","LU2750360641.GBP","LU0466842654.USD","LU2264538146.SGD","LU2471134879.HKD","LU2552382132.HKD","ABBV","LU1061106388.HKD","LU0320765059.SGD","LU1917777945.USD","LU2265009873.SGD","LU1057294990.SGD","LU1064131342.USD","LU0256863902.USD","LU2063271972.USD","LU0316494557.USD","LU0820561818.USD","LU1720051017.SGD","LU2237443549.SGD","LU0689472784.USD","SGXZ31699556.SGD","LU0640476718.USD","LLY","BK4599","IE00BJT1NW94.SGD","IE00B1BXHZ80.USD","LU0238689110.USD","SGXZ81514606.USD","LU2461242641.AUD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2540928637","title":"明晟公司MSCI北欧国家指数涨0.6%，报358.57点，北欧医疗保健板块领跑。诺和诺德涨4.7%，领跑一众成分股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2540928637","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540928637?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 23:50","pubTimestamp":1748879422,"startTime":"0","endTime":"0","summary":"明晟公司MSCI北欧国家指数涨0.6%，报358.57点，北欧医疗保健板块领跑。诺和诺德涨4.7%，领跑一众成分股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/02235050812871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BKVL7J92.USD","MSCI","LU2265009873.SGD","LU0320765059.SGD","BK4532","BK4588","LU0672654240.SGD","LU2095319765.USD","BK4112","LU0511384066.AUD","BK4585","IE00BZ1G4Q59.USD","BK4599","LU0109391861.USD","LU0289961442.SGD","LU0154236417.USD","LU2210150020.SGD","LU1267930730.SGD","LU0708995401.HKD","LU0289739343.SGD","LU1093756168.USD","LU0175139822.USD","LU1093756325.SGD","LU1804176565.USD","NVO","BK4007","LU2210149790.SGD","LU0289960550.SGD"],"gpt_icon":0},{"id":"2540799269","title":"Altimmune, Inc.盘中异动 早盘急速下跌5.16%报5.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540799269","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540799269?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 22:04","pubTimestamp":1748873041,"startTime":"0","endTime":"0","summary":"北京时间2025年06月02日22时04分，Altimmune, Inc.股票出现异动，股价快速下挫5.16%。截至发稿，该股报5.15美元/股，成交量47.9556万股，换手率0.59%，振幅6.54%。Altimmune, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。Altimmune, Inc.公司简介：Altimmune Inc 是一家处于临床阶段的生物制药公司，专注于开发针对肥胖症、代谢性疾病和肝脏疾病的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602220401a496c4a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250602220401a496c4a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4599","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2540376029","title":"安进公司药物可将小细胞肺癌死亡风险降低 40","url":"https://stock-news.laohu8.com/highlight/detail?id=2540376029","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540376029?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 20:00","pubTimestamp":1748865641,"startTime":"0","endTime":"0","summary":"安进公司药物可将小细胞肺癌死亡风险降低 40Imdelltra将中位生存期延长了5个多月27%的Imdelltra患者出现严重副作用，而化疗患者的这一比例为62%。试验结果旨在支持该药物的加速审批 Deena Beasley路透社6月2日 - 安进公司AMGN.O的Imdelltra与化疗相比，可将首轮化疗后病情恶化的小细胞肺癌患者的死亡风险降低40%。安进公司说，细胞因子释放综合征是当人体免疫系统对感染或免疫疗法药物做出过激反应时出现的一种潜在危险症状，主要是低度和可控的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nL3S3S50SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242652126.USD","SG9999001440.SGD","BK4534","BK4581","LU1023059063.AUD","LU1061106388.HKD","LU1983299246.USD","LU2089984988.USD","BK4139","LU1057294990.SGD","AMGN","BK4599","IE00B4R5TH58.HKD","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","LU0109394709.USD","LU2468319806.SGD","BK4585","LU2112291526.USD","BK4588","LU0289739699.SGD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU0868494617.USD","LU2242646821.SGD","BK4533","LU0122379950.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4566","LU0320765992.SGD"],"gpt_icon":0},{"id":"2540803707","title":"辉瑞占先发优势，Alnylam、BridgeBio紧跟，ATTR-CM三强鏖战","url":"https://stock-news.laohu8.com/highlight/detail?id=2540803707","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540803707?lang=zh_cn&edition=fundamental","pubTime":"2025-06-01 08:03","pubTimestamp":1748736216,"startTime":"0","endTime":"0","summary":"2024年11月，BridgeBio公司开发的TTR稳定剂Attruby也获得FDA批准用于治疗ATTR-CM成年患者，目前销售势头良好。Alnylam公司首席商务官Tolga Tanguler认为，相较tafimidis或BridgeBio公司的Attruby需每日口服给药，Amvuttra全年仅需进行4次皮下注射给药，有望提高患者依从性。但是，BridgeBio公司认为，其药物在稳定TTR方面的效果优于辉瑞的产品。辉瑞优势地位暂时无忧虽然Alnylam公司和BridgeBio公司都在挑战辉瑞，但从销售额来看，辉瑞目前仍居有利地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250601083413a494b83d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250601083413a494b83d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0122379950.USD","BK4533","LU1023059063.AUD","SG9999001176.SGD","CM","SG9999011175.SGD","PFE","BK4207","LU0058720904.USD","BK4581","IE000M9KFDE8.USD","LU0289739699.SGD","LU0225284248.USD","LU0456855351.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","BK4592","IE00B19Z3B42.SGD","LU1066051498.USD","LU1066053197.SGD","BK4599","BK4568","LU1894683348.USD","IE00BLSP4452.SGD","LU1883839398.USD","BK4550","SG9999002232.USD","SG9999013999.USD","IE0002270589.USD","BK4588","LU0170899867.USD","BK4007","SG9999003800.SGD","LU1057294990.SGD","LU0985481810.HKD","IE00BLSP4239.USD","SG9999002224.SGD","LU0321505868.SGD","BK4585","LU1894683264.USD","SG9999001176.USD","BK4534","LU0225771236.USD","LU0306807586.USD","IE00B19Z3581.USD","LU0321505439.SGD","LU0234572021.USD","LU0306806265.USD","LU0868494617.USD"],"gpt_icon":1},{"id":"2539853204","title":"辉瑞：2 款创新 ADC 联合 K 药数据首次公布！恩扎卢胺 5 年 OS 率超 65 %...","url":"https://stock-news.laohu8.com/highlight/detail?id=2539853204","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539853204?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 08:34","pubTimestamp":1748651646,"startTime":"0","endTime":"0","summary":"结果显示，与安慰剂 + ADT 相比，使用恩扎卢胺 + ADT 治疗的受试者获得了 OS 获益，死亡风险降低了 30%。所有 HNSCC 患者的 PD-L1  CPS 评分均为 ≥1。任何等级和 ≥3 级免疫介导的 TEAE 发生率分别为 61% 和 10%。截至 2024 年 12 月 20 日，已有 14 名患者接受给药，中位年龄为 61 岁。全球首创 KAT6 抑制剂即将开展 III 期临床此次辉瑞在 ASCO 大会上公布的是首创 KAT6 抑制剂 PF-07248144 治疗 ER+/HER2- 转移性乳腺癌的 I 期更新临床数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531083822a6f3fdba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531083822a6f3fdba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4581","IE00B19Z3B42.SGD","LU0170899867.USD","LU1066053197.SGD","SG9999001176.SGD","SG9999001176.USD","BK4080","LU0122379950.USD","SG9999002232.USD","LU0225771236.USD","PFE","BK4550","LU1883839398.USD","SGXZ57979304.SGD","BK4592","IE00BBT3K403.USD","IE000M9KFDE8.USD","BK4588","ADC","BK4534","LU1894683348.USD","LU0321505868.SGD","BK4568","LU0058720904.USD","BK4599","LU1023059063.AUD","LU0985481810.HKD","LU1057294990.SGD","BK4585","IE0002270589.USD","LU0456855351.SGD","LU0321505439.SGD","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","BK4533","LU0306806265.USD","SG9999011175.SGD","SG9999003800.SGD","LU0306807586.USD","LU0289739699.SGD","LU1066051498.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","BK4007","BK4231","LU0234572021.USD","LU1894683264.USD","IE00B19Z3581.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"2539277430","title":"诺和诺德盘中异动 急速上涨3.02%报71.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539277430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539277430?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 03:37","pubTimestamp":1748633859,"startTime":"0","endTime":"0","summary":"北京时间2025年05月31日03时37分，诺和诺德股票出现异动，股价大幅上涨3.02%。截至发稿，该股报71.56美元/股，成交量850.342万股，换手率0.19%，振幅3.56%。诺和诺德股票所在的制药行业中，整体涨幅为1.88%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。方正证券研报指出，截至2024年7月1日，国内已有31款具有减重适应证的GLP-1创新类药物进入临床申请及临床试验阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531033740976b88ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250531033740976b88ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","LU1093756168.USD","LU0154236417.USD","IE00BKVL7J92.USD","BK4588","BK4585","BK4007","LU1093756325.SGD","BK4599","IE00BZ1G4Q59.USD","NVO"],"gpt_icon":1},{"id":"2539277552","title":"美国疾病预防控制中心继续推荐健康儿童接种 COVID 疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2539277552","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539277552?lang=zh_cn&edition=fundamental","pubTime":"2025-05-31 03:17","pubTimestamp":1748632669,"startTime":"0","endTime":"0","summary":"更新 1-美国疾病预防控制中心继续推荐健康儿童接种 COVID 疫苗更改了来源，在第 4-5 段中增加了背景信息。路透社华盛顿5月30日 - 根据美国疾病控制与预防中心最新公布的免疫接种计划，该中心仍建议健康儿童接种 COVID-19 疫苗。美国疾病预防控制中心在其外部专家小组会议之后，曾建议为所有年龄在六个月及以上的人接种更新的 COVID 疫苗，目前的建议与之前的建议一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nL3S3S214J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","LU1894683348.USD","BK4501","IE00BBT3K403.USD","BK4139","BK4550","LU0289739699.SGD","LU0321505868.SGD","LU0234572021.USD","LU0456855351.SGD","LU0225771236.USD","IE000M9KFDE8.USD","BK4532","BK4548","BK4533","BK4547","BK4007","LU0985481810.HKD","BK4599","LU1066053197.SGD","LU0058720904.USD","LU1066051498.USD","BK4592","LU1883839398.USD","LU0306807586.USD","SG9999011175.SGD","NVAX","SG9999013999.USD","BK4551","IE0002270589.USD","SG9999003800.SGD","BK4568","LU0170899867.USD","SG9999002224.SGD","LU1023059063.AUD","SGXZ57979304.SGD","IE00BLSP4239.USD","SG9999001176.USD","LU0122379950.USD","BK4534","BK4581","LU1057294990.SGD","IE00B19Z3581.USD","PFE","LU1894683264.USD","MRNA","IE00B19Z3B42.SGD","BK4588","SG9999001176.SGD","LU0868494617.USD"],"gpt_icon":1},{"id":"2539211573","title":"辉瑞5月29日成交额为6.12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539211573","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539211573?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 11:41","pubTimestamp":1748576506,"startTime":"0","endTime":"0","summary":"美东时间2025年5月29日，辉瑞成交额为6.12亿美元，成交额较昨日减少28.44%，当日成交量为2621.01万股。辉瑞于2025年5月29日涨1.16%，报23.45美元，该股过去5个交易日涨1.78%，年初至今跌8.43%，过去60日跌7.2%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-29|6.12亿|-28.44%|2621.01万|#|2025-05-28|8.56亿|0.45%|3673.72万|#|2025-05-27|8.52亿|3.57%|3615.54万|#|2025-05-23|8.22亿|-7.29%|3540.54万|#|2025-05-22|8.87亿|-11.16%|3860.28万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530114149a492301f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530114149a492301f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023059063.AUD","LU0234572021.USD","BK4581","LU1894683264.USD","BK4534","LU1883839398.USD","BK4588","LU0306807586.USD","LU1894683348.USD","IE00B19Z3581.USD","SGXZ57979304.SGD","BK4007","LU0225771236.USD","LU0058720904.USD","LU1057294990.SGD","SG9999002224.SGD","LU0306806265.USD","LU0289739699.SGD","LU0321505868.SGD","LU0985481810.HKD","LU1066051498.USD","LU1066053197.SGD","SG9999001176.SGD","BK4568","LU0868494617.USD","BK4533","BK4592","IE000M9KFDE8.USD","LU0170899867.USD","IE0002270589.USD","LU0225284248.USD","LU0321505439.SGD","SG9999002232.USD","IE00BLSP4239.USD","LU0122379950.USD","BK4550","IE00B19Z3B42.SGD","SG9999013999.USD","SG9999011175.SGD","IE00BBT3K403.USD","BK4585","IE00BLSP4452.SGD","BK4599","LU0456855351.SGD","PFE","SG9999003800.SGD","SG9999001176.USD"],"gpt_icon":1},{"id":"2539749213","title":"安进5月29日成交额为7.91亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2539749213","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539749213?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 09:16","pubTimestamp":1748567771,"startTime":"0","endTime":"0","summary":"美东时间2025年5月29日，安进成交额为7.91亿美元，成交额较昨日减少26.62%，当日成交量为280.24万股。安进于2025年5月29日涨1.85%，报283.54美元，该股过去5个交易日涨4.5%，年初至今涨10.64%，过去60日跌8.37%。安进于 2006 年推出了首款癌症治疗药物 Vectibix，并销售骨强化药物 Prolia/Xgeva和 Evenity。同时，安进还拥有不断增长的生物仿制药产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530091624a4920a0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530091624a4920a0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","AMGN","LU1057294990.SGD","IE00B4R5TH58.HKD","LU0122379950.USD","LU0109394709.USD","BK4599","LU2089984988.USD","LU2112291526.USD","LU2242652126.USD","LU1983299246.USD","BK4588","LU0320765992.SGD","BK4534","IE00BFTCPJ56.SGD","LU2242646821.SGD","IE0009355771.USD","LU1061106388.HKD","LU1571399168.USD","BK4533","LU1023059063.AUD","BK4566","LU0868494617.USD","LU2468319806.SGD","BK4585","BK4139","BK4581","IE0002141913.USD","LU0058720904.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","IE00BJT1NW94.SGD","SG9999001440.SGD"],"gpt_icon":0},{"id":"2539923772","title":"财说｜一桩交易重构双抗药物市场，康方生物为何“受伤”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2539923772","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539923772?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 08:00","pubTimestamp":1748563200,"startTime":"0","endTime":"0","summary":"康方生物为何受伤？资本市场表现上，康方生物与Summit均短线下跌。SSGJ-707和AK112均为PD-1/VEGF双抗，分别由三生制药和康方生物主导研发，靶点机制一致，适应症布局高度重叠。因此，两款药物在全球PD-1/VEGF双抗市场将不可避免地产生正面竞争关系。康方生物目前仍存在较大财务压力。康方生物通过授权带来5亿美元首付款，但尚无后续临床或销售里程碑收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530080306a6f279fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250530080306a6f279fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0321505439.SGD","LU1894683348.USD","IE00BBT3K403.USD","BK4550","LU0289739699.SGD","LU0321505868.SGD","LU0234572021.USD","LU0456855351.SGD","LU0306806265.USD","LU0225771236.USD","IE000M9KFDE8.USD","BK4533","SG9999002232.USD","BK4007","LU0985481810.HKD","BK4599","LU1066053197.SGD","LU0058720904.USD","LU1066051498.USD","BK4592","LU1883839398.USD","LU0306807586.USD","SG9999011175.SGD","SG9999013999.USD","IE0002270589.USD","SG9999003800.SGD","BK4568","LU0225284248.USD","LU0170899867.USD","SG9999002224.SGD","LU1023059063.AUD","IE00BLSP4452.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","SG9999001176.USD","LU0122379950.USD","BK4585","BK4534","BK4581","LU1057294990.SGD","IE00B19Z3581.USD","LU1894683264.USD","IE00B19Z3B42.SGD","BK4588","SG9999001176.SGD","LU0868494617.USD"],"gpt_icon":1},{"id":"2539777260","title":"健康查房：安进公司的血小板促进剂帮助需要化疗的患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2539777260","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539777260?lang=zh_cn&edition=fundamental","pubTime":"2025-05-30 02:17","pubTimestamp":1748542629,"startTime":"0","endTime":"0","summary":"Nplate 的作用是刺激骨髓增加血小板的生成。而安慰剂组中只有36%的患者需要减少化疗剂量。他指出，目前美国食品和药物管理局还没有批准治疗化疗引起的血小板减少的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nL3S3S11FJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1487256676.USD","LU0171293334.USD","LU0661504455.SGD","LU1323610961.USD","LU0545039389.USD","LU0868494617.USD","LU0553294199.USD","IE0002141913.USD","LU1261432733.SGD","LU1023059063.AUD","LU1267930490.SGD","LU0964806797.USD","LU0708994859.HKD","LU0077335932.USD","LU1153584641.USD","AZN.UK","LU2242646821.SGD","LU2089984988.USD","SG9999001176.SGD","AMGN","IE0009355771.USD","BK4585","SG9999013999.USD","LU0575583348.USD","LU1301847155.USD","BK4599","LU0128525929.USD","LU1880407215.USD","LU1989772923.USD","LU1019632923.USD","LU1267930573.SGD","688235","BK4566","BK5011","LU0211326839.USD","LU1119994496.HKD","LU1078025761.USD","IE00B2B36J28.USD","03165","LU0526926950.USD","LU2112291526.USD","LU0289739699.SGD","IE00BKPKM643.USD","LU0784383803.USD","LU1061106388.HKD","LU0499090636.EUR","LU1571399168.USD","LU0972486137.USD","LU1051770623.HKD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2539991250","title":"礼来反超：减肥药市场\"老二\"如何击败\"老大\"诺和诺德","url":"https://stock-news.laohu8.com/highlight/detail?id=2539991250","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539991250?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 20:11","pubTimestamp":1748520694,"startTime":"0","endTime":"0","summary":"诺和诺德的败局始于低估需求的“致命错误”，供应短缺为礼来突围打开了大门，同时研发管线失守、营销策略滞后也导致诺和诺德落后于礼来。","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3748124","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3748124","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2750360641.GBP","BK4516","LU0823416689.USD","LU2491049909.HKD","LU2237443549.SGD","LU2237443978.SGD","LU0289739699.SGD","LU0320765059.SGD","LU1868836914.USD","LLY","LU2237438978.USD","LU1232071149.USD","LU1720051017.SGD","LU2112291526.USD","LU0079474960.USD","SGXZ51526630.SGD","LU1064131342.USD","LU1093756168.USD","SG9999015945.SGD","LU2491050071.SGD","BK4585","LU2211815571.USD","LU2361045086.USD","LU1988902786.USD","LU2023250504.SGD","SG9999018857.SGD","LU2237443895.HKD","BK4599","IE00BJT1NW94.SGD","SG9999013999.USD","NVO","LU0198837287.USD","LU0114720955.EUR","LU0266013472.USD","IE0009355771.USD","LU2471134796.USD","SG9999014914.USD","SG9999014880.SGD","LU0094547139.USD","LU2552382132.HKD","LU1983299246.USD","LU1868836757.USD","LU2089984988.USD","LU2552382058.USD","LU2361044949.HKD","LU0323591593.USD","LU1548497426.USD","LU0109391861.USD","BK4532","LU2471134952.CNY"],"gpt_icon":1},{"id":"2539235276","title":"平安健康携手诺和诺德，开创肥胖症管理服务新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2539235276","media":"企业观察网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539235276?lang=zh_cn&edition=fundamental","pubTime":"2025-05-29 14:40","pubTimestamp":1748500800,"startTime":"0","endTime":"0","summary":"2025年5月13日，平安健康与诺和诺德中国正式宣布达成战略合作，双方将整合各自在肥胖症管理及公众健康教育领域的优势资源，共同构建覆盖“认知提升 - 诊疗干预 - 长期管理”的全周期服务闭环，推动科学减重理念落地。近年来，肥胖问题已成为我国重大公共卫生挑战。此次平安健康与诺和诺德的合作，正是积极响应国家体重管理政策的创新之举。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052914403997697195&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052914403997697195&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4585","LU0154236417.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4599","NVO","BK4588","LU1093756168.USD","BK4007","IE00BKVL7J92.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}